| Authors: |
Karasarides M; Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey., Cogdill AP; Immunai, New York, New York.; Department of Immunology, The University of Texas MD Anderson, Houston, Texas., Robbins PB; Instil Bio, Dallas, Texas., Bowden M; Translational Medicine, Bristol Myers Squibb, Cambridge, Massachusetts., Burton EM; Department of Surgical Oncology, The University of Texas MD Anderson, Houston, Texas., Butterfield LH; Parker Institute for Cancer Immunotherapy, San Francisco, California.; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California., Cesano A; ESSA Pharma Inc., South San Francisco, California., Hammer C; Department of Cancer Immunology, Genentech, South San Francisco, California.; Department of Human Genetics, Genentech, South San Francisco, California., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Horak CE; Global Drug Development, Bristol Myers Squibb, Lawrenceville, New Jersey., McGee HM; Department of Radiation Oncology, City of Hope National Medical Center and Department of Immuno-Oncology, Beckmann Research Institute, City of Hope, Duarte, California., Monette A; Lady Davis Institute for Medical Research, Montréal, Québec, Canada., Rudqvist NP; University of Texas MD Anderson Cancer Center, Houston, Texas., Spencer CN; Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, California.; University of California San Francisco, San Francisco, California., Sweis RF; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.; Committee on Immunology, University of Chicago, Chicago, Illinois.; Comprehensive Cancer Center, University of Chicago, Chicago, Illinois., Vincent BG; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina., Wennerberg E; The Institute of Cancer Research, London, UK., Yuan J; Translational Oncology, Early Oncology Development Department, Merck Research Laboratories, Rahway, New Jersey., Zappasodi R; Weill Cornell Medicine, New York, New York.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York.; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York., Lucey VMH; Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey., Wells DK; Immunai, New York, New York.; Parker Institute for Cancer Immunotherapy, San Francisco, California., LaVallee T; Parker Institute for Cancer Immunotherapy, San Francisco, California. |
